Impax Asset Management Group plc Acquires 100,000 Shares of Enovis Corporation $ENOV

Impax Asset Management Group plc raised its holdings in shares of Enovis Corporation (NYSE:ENOV) by 47.5% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 310,630 shares of the company’s stock after acquiring an additional 100,000 shares during the period. Impax Asset Management Group plc’s holdings in Enovis were worth $9,425,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. Hood River Capital Management LLC lifted its stake in shares of Enovis by 20.3% in the 2nd quarter. Hood River Capital Management LLC now owns 1,735,533 shares of the company’s stock valued at $54,426,000 after acquiring an additional 292,950 shares during the last quarter. River Road Asset Management LLC lifted its position in Enovis by 3.5% in the second quarter. River Road Asset Management LLC now owns 1,439,923 shares of the company’s stock valued at $45,156,000 after purchasing an additional 48,036 shares during the last quarter. Boston Partners boosted its stake in shares of Enovis by 42.4% during the second quarter. Boston Partners now owns 1,382,724 shares of the company’s stock valued at $43,352,000 after purchasing an additional 411,744 shares during the period. Geode Capital Management LLC boosted its stake in shares of Enovis by 43.8% during the second quarter. Geode Capital Management LLC now owns 1,342,481 shares of the company’s stock valued at $42,105,000 after purchasing an additional 408,608 shares during the period. Finally, Tributary Capital Management LLC grew its holdings in shares of Enovis by 91.5% in the third quarter. Tributary Capital Management LLC now owns 1,154,482 shares of the company’s stock worth $35,027,000 after purchasing an additional 551,613 shares during the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Insider Activity at Enovis

In other news, insider John Kleckner acquired 2,468 shares of the business’s stock in a transaction on Tuesday, November 25th. The shares were acquired at an average cost of $30.32 per share, with a total value of $74,829.76. Following the transaction, the insider owned 12,302 shares in the company, valued at $372,996.64. The trade was a 25.10% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Daniel A. Pryor sold 999 shares of the stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $27.20, for a total value of $27,172.80. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 2.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ENOV. BTIG Research began coverage on shares of Enovis in a report on Tuesday, January 6th. They set a “buy” rating and a $41.00 price target for the company. Evercore reaffirmed an “outperform” rating on shares of Enovis in a research note on Monday, January 12th. Wells Fargo & Company increased their target price on shares of Enovis from $41.00 to $42.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Canaccord Genuity Group reduced their price target on Enovis from $58.00 to $50.00 and set a “buy” rating on the stock in a report on Wednesday, December 17th. Finally, UBS Group reaffirmed a “buy” rating and set a $50.00 price target on shares of Enovis in a research report on Monday, January 5th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $46.71.

Enovis Trading Up 0.9%

Shares of ENOV opened at $22.77 on Thursday. Enovis Corporation has a 1-year low of $21.00 and a 1-year high of $44.76. The company has a current ratio of 2.22, a quick ratio of 1.16 and a debt-to-equity ratio of 0.66. The firm’s 50-day moving average price is $25.32 and its 200-day moving average price is $28.57. The firm has a market capitalization of $1.30 billion, a price-to-earnings ratio of -0.96 and a beta of 1.52.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.